Synairgen Stock Soars 420% On Promise Of Inhaled COVID-19 Drug
Small Study Excites Investors
Preliminary results show that hospitalized coronavirus patients who received Synairgen's inhaled interferon beta product had a 79% lower risk of developing severe disease compared with placebo.
